The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis

Swerdlow, D.I. et al. (2012) The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet, 379(9822), pp. 1214-1224. (doi:10.1016/S0140-6736(12)60110-X)

Full text not currently available from Enlighten.


Background: A high circulating concentration of interleukin 6 is associated with increased risk of coronary heart disease. Blockade of the interleukin-6 receptor (IL6R) with a monoclonal antibody (tocilizumab) licensed for treatment of rheumatoid arthritis reduces systemic and articular inflammation. However, whether IL6R blockade also reduces risk of coronary heart disease is unknown. Methods: Applying the mendelian randomisation principle, we used single nucleotide polymorphisms (SNPs) in the gene IL6R to evaluate the likely efficacy and safety of IL6R inhibition for primary prevention of coronary heart disease. We compared genetic findings with the effects of tocilizumab reported in randomised trials in patients with rheumatoid arthritis. Findings: In 40 studies including up to 133 449 individuals, an IL6R SNP (rs7529229) marking a non-synonymous IL6R variant (rs8192284; p.Asp358Ala) was associated with increased circulating log interleukin-6 concentration (increase per allele 9.45%, 95% CI 8.34-10.57) as well as reduced C-reactive protein (decrease per allele 8.35%, 95% CI 7.31-9.38) and fibrinogen concentrations (decrease per allele 0.85%, 95% CI 0.60-1.10). This pattern of effects was consistent with IL6R blockade from infusions of tocilizumab (4-8 mg/kg every 4 weeks) in patients with rheumatoid arthritis studied in randomised trials. In 25 458 coronary heart disease cases and 100 740 controls, the IL6R rs7529229 SNP was associated with a decreased odds of coronary heart disease events (per allele odds ratio 0.95, 95% CI 0.93-0.97, p=1.53x10(-5)). Interpretation: On the basis of genetic evidence in human beings, IL6R signalling seems to have a causal role in development of coronary heart disease. IL6R blockade could provide a novel therapeutic approach to prevention of coronary heart disease that warrants testing in suitably powered randomised trials. Genetic studies in populations could be used more widely to help to validate and prioritise novel drug targets or to repurpose existing agents and targets for new therapeutic uses.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Ford, Professor Ian and Sattar, Professor Naveed
Authors: Swerdlow, D.I., Holmes, M.V., Kuchenbaecker, K.B., Engmann, J.E.L., Shah, T., Sofat, R., Guo, Y.R., Chung, C., Peasey, A., Ster, R.P., Mooijaart, S.P., Ireland, H.A., Leusink, M., Langenberg, C., Li, K., Palmen, J., Howard, P., Cooper, J.A., Drenos, F., Hardy, J., Nalls, M.A., Li, Y.R., Lowe, G., Stewart, M., Bielinski, S.J., Peto, J., Timpson, N.J., Gallacher, J., Dunlop, M., Houlston, R., Tomlinson, I., Tzoulaki, I., Luan, J., Boer, J.M.A., Forouhi, N.G., Onland-Moret, N.C., van der Schouw, Y.T., Schnabel, R.B., Hubacek, J.A., Kubinova, R., Baceviviene, M., Tamosiunas, A., Pajak, A., Topor-Madry, R., Malyutina, S.A., Baldassarre, D., Sennblad, B., Tremoli, E., de Faire, U., Ferrucci, L., Bandenelli, S., Tanaka, T., Meschia, J.F., Singleton, A., Navis, G., Leach, I.M., Bakker, S.J.L., Gansevoort, R.T., Ford, I., Epstein, S.E., Burnett, M.S., Devaney, J.M., Jukema, J.W., Westendorp, R.G.J., de Borst, G.J., van der Graaf, Y., de Jong, P.A., Maitland-van der Zee, A.H., Klungel, O.H., de Boer, A., Doevendans, P.A., Stephens, J.W., Eaton, C.B., Robinson, J.G., Manson, J.E., Fowkes, F.G.R., Frayling, T.M., Price, J.F., Whincup, P.H., Morris, R.W., Lawlor, D.A., Smith, G.D., Ben-Shlomo, Y., Redline, S., Lange, L.A., Kumari, M., Wareham, N.J., Verschuren, W.M.M., Benjamin, E.J., Whittaker, J.C., Hamsten, A., Dudbridge, F., Delaney, J.A.C., Wong, A., Kuh, D., Hardy, R., Castillo, B.A., Connolly, J.J., van der Harst, P., Brunner, E.J., Marmot, M.G., Wassel, C.L., Humphries, S.E., Talmud, P.J., Kivimaki, M., Asselbergs, F.W., Voevoda, M., Bobak, M., Pikhart, H., Wilson, J.G., Hakonarson, H., Reiner, A.P., Keating, B.J., Sattar, N., Hingorani, A.D., and Casas, J.P.
Subjects:R Medicine > R Medicine (General)
College/School:College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Robertson Centre
College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:Lancet
Publisher:The Lancet Publishing Group
Published Online:14 March 2012

University Staff: Request a correction | Enlighten Editors: Update this record